PacGate Law Group

Beijing Office

Current View:

This content is provided by PacGate Law Group.

Chairman: Yigong (Justin) CHEN
Managing Partner: Yigong (Justin) CHEN
Number of partners: 10
Number of lawyers: 32
Languages: Chinese, English

Firm Overview:
PacGate Law Group is a professional boutique law firm that is committed to providing premium legal services to their clients, who consist mainly of business entities and institutional investors. They pride themselves on combining their domestic and international experiences to offer clients professional, business-oriented, and cost-effective legal services on complex transactional matters. Their services cover a wide range of legal practice areas, such as PE & VC, investment fund, M&A, financial services, securities and capital market, foreign direct investment (FDI), overseas investment, and dispute resolution. Their clients are from a variety of industries, including TMT & Internet, healthcare and pharmaceuticals, biotechnology, entertainment, high technology, energy and resources, technology finance, education, tourism, communication, consumer products & retail, real estate, and logistics.

Main Areas of Practice:
Private Equity & Venture Capital:
6 partners; 26 fee earners based in Beijing
■ Representation of JD.com in its investment of Giga Cloud Logistics (it’s the largest singleround financing project in the export B2B field in 2020)
■ Representation of New Horizon Health’s US$66 million Series C financing (it’s the largest investment so far in the field of early cancer screening in China)
■ Representation of Betta Pharmaceuticals to introduce the license of PD-1 and CTLA-4
■ Representation of JD Health’s equity investment in Weining Technology
Key Clients: SB China Capital (SBCVC), Northern Light Venture Capital, Infinity Ventures Partners, Kaiwu Capital, JMCR Partners, F&G Ventures, Honghua Capital, F & G Venture, DerbySoft (Shanghai), Dingdang Medicine Express, Tong Ren Tang, Bank of Communications Beijing Branch
Contact: Elva WANG
Tel: + 86.10.6530 9989
Email: [email protected]

Investment Funds:
5 partners; 21 fee earners based in Beijing
■ Representation of JD Logistics on the establishment of its first 1.5 billion RMB industrial fund
■ Representation of Huaxing Growth Capital on the establishment of its 1st, 2nd and 3rd phase RMB funds
■ Representation of Digital China Capital Co., Ltd on the establishment of its RMB fund
■ Representation of Honghua Capital on the establishment of special RMB fund for its investment in Lianjia, Luoji Siwei, and Missfresh
Key Clients: Huaxing Medical Ttreatment Industry Fund, Vision Ventures, Skyview Fund, Everbright Haiyin Fund, PYX Fund, Essential Capital, Frontier Capital
Contact: Elva WANG
Tel: + 86.10.6530 9989
Email: [email protected]

Mergers & Acquisitions:
4 partners; 24 fee earners based in Beijing
■ Representation of JD.com in its acquisition of Beijing Youjike Technology Co., Ltd., Nuanxin Yiliao, Shanghai Darong Express Co., Ltd.
■ Representation of Dajie Net in its acquisition by Meitu
■ Representation of Northern Light Venture Capital in its acquisition of shares held by Wanwang, Tianyundun, Shanghai Douwu, and CIBN
Key Clients: 3E Bioventures, Betta Pharmaceuticals, ShineON, Gensee, SEED, China Traffic, Redbaby , 17APP, Perfect World, Frankenman
Contact: Elva WANG
Tel: + 86.10.6530 9989
Email: [email protected]

Securities & Capital Market:
4 partners; 18 fee earners based in Beijing
■ Representation of NASDAQ’s public offering of Chinese concept stocks WIMIi Holographic
■ Representation of Lexin (NASDAQ:LX) for its overseas restructuring before listing
■ Representation of Ambow Education (NYSE:AMBO) in the preparation of legal documents before listing
■ Representation of Qihoo 360 (NYSE:QIHU) in its privatization
■ Representation of Hudong Baike in the preparation of legal documents before listing
Key Clients: Caissa Touristic (000796), Focused Photonics Inc. (SZ.300203), Lianluo Hudong (002280), Torque Esports Corp. (NASDAQ:GAME)
Contact: Elva WANG
Tel: + 86.10.6530 9989
Email: [email protected]

Healthcare & Pharmaceuticals:
3 partners; 14 fee earners based in Beijing
■ Representation of JD Health’s equity investment in Weining Technology
■ Representation of Betta Pharmaceuticals to introduce the license of PD-1 and CTLA-4
■ Representation of Anlong in its investment of Inmagene
■ Representation of New Horizon Health for its US$66 million Series C financing (it’s the largest financing so far in the field of early cancer screening in China)
■ Representation of Dingdang Medicine Express for its 600 million RMB new round of financing
Key Clients: 3E Bioventures, Viva Biotech, AglaeaPharma, China Parma Holdings, HitGen, Adagene, Frankenman, Marvogen, MingSight, Eivogen
Contact:
Elva WANG
Tel: + 86.10.6530 9989
Email: [email protected]